The mesothelioma market reached a value of USD 536.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 698.6 Million by 2035, exhibiting a growth rate (CAGR) of 2.27% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 536.2 Million |
Market Forecast in 2035
|
USD 698.6 Million |
Market Growth Rate 2025-2035
|
2.27% |
The mesothelioma market has been comprehensively analyzed in IMARC's new report titled "Mesothelioma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Mesothelioma refers to a type of cancer that affects the thin layer of tissue (mesothelium) covering the internal organs of the body. The symptoms of the ailment can vary depending on the location of the cancer, but the most common form, pleural mesothelioma, typically presents with indications like coughing, chest pain, shortness of breath, etc. Numerous other manifestations may include fatigue, weight loss, difficulty swallowing, etc. In some cases, patients may also experience abdominal pain and swelling. A definitive diagnosis of the disease can be challenging due to its similarity to other conditions, so a comprehensive evaluation by an experienced team is essential for an accurate prognosis. The diagnostic process may include imaging procedures, such as X-rays, CT scans, MRIs, etc., as well as biopsies to examine tissue samples for signs of cancer. Doctors may also perform pulmonary function tests to evaluate lung function and blood tests to look for biomarkers associated with mesothelioma.
The increasing cases of exposure to asbestos fibers, which become lodged in the lining of the lungs, abdomen, or heart, and cause irritation as well as inflammation, are primarily driving the mesothelioma market. Besides this, the widespread adoption of pleurectomy with decortication for relieving symptoms, such as chest pain and difficulty breathing, and improving survival rates in patients is also propelling the market growth. Furthermore, the escalating utilization of chemotherapy in combination with various other treatments, including surgery or radiation therapy, to shrink tumor size and slow the progression of mesothelioma is acting as another significant growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to introduce targeted therapies that target specific molecules or pathways involved in the formation and spread of cancer cells. This, in turn, is also creating a positive outlook for the market. Moreover, the introduction of high-resolution CT scanning for detecting abnormalities in the lungs or pleura, which may be indicative of the disease, is expected to drive the mesothelioma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the mesothelioma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for mesothelioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mesothelioma market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current mesothelioma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Alimta (Pemetrexed) | Eli Lilly and Company |
Yervoy (Ipilimumab) | Bristol Myers Squibb |
Opdivo (Nivolumab) | Bristol-Myers Squibb/Ono Pharmaceuticals |
MTG 201 | Momotaro-Gene |
IAG933 | Novartis Pharmaceuticals |
RSO-021 | RS Oncology |
MesoPher | Amphera |
Durvalumab (MEDI4736) | PrECOG, LLC. |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Mesothelioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies